CRYAA and Parkinson disease: In Parkinson’s disease (PD), HSPB4 has been shown to be the most potent inhibitor, in an autophagy-independent fashion, of disease-causing protein aggregates induced by the C289G parkin E3-ubiquitin protein ligase (PARK2) mutation [135].